New data on the effectiveness of sebetralstat in children and adults to be presented at major global conference
The latest data on a new medicine for HAE, called Ekterly (sebetralstat), will be presented at the forthcoming American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida, from 6-10 November 2025.
The pharmaceutical company behind sebetralstat, KalVista, confirmed the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the conference. These are:
Distinguished Industry & Late-breaking Oral Abstracts – Session 1 on Saturday 8 November, in room W230CD:
- Sebetralstat for on-demand treatment of hereditary angioedema in pediatric (2-11y) patients: Interim results from KONFIDENT-KID
ePosters – Meet the Authors: Session One on Friday 7 November, in West Hall E:
- Satisfaction with sebetralstat for HAE attacks in patients switching from parenteral on-demand treatments in KONFIDENT-S
- A Delphi consensus study on the barriers to on-demand treatment for hereditary angioedema attacks
- Hereditary angioedema patient and expert physician alignment on a novel oral on-demand therapy
(Source: KalVista)
